ACAD
32.11
+0.22
+0.69%
AEMD
1.59
-0.09
-5.36%
APRI
1.35
0.00
0.00%
ARNA
21.27
-0.12
-0.56%
ATEC
1.68
-0.01
-0.59%
CNAT
5.06
-0.1
-1.94%
CRXM
0.159
+0.001
+0.72152%
CYTX
0.35
-0.02
-4.40%
DXCM
71.22
-0.4
-0.56%
GNMK
9.99
-0.1
-0.99%
HALO
11.9
-0.15
-1.24%
ILMN
193.92
-0.88
-0.45%
INNV
0.109
+0.008
+7.921%
INO
5.64
0.00
0.00%
ISCO
1.3
-0.05
-3.70%
ISIS
57.56
0.00
0.00%
LGND
127.02
+0.1
+0.08%
LPTN
2.93
-2.93
-100.00%
MBVX
0.511
-0.04
-7.1818%
MEIP
2.77
-0.02
-0.72%
MNOV
4.69
+0.09
+1.96%
MRTX
4.9
+0.05
+1.03%
MSTX
0.13
-0.01
-5.28%
NBIX
54.04
+0.06
+0.11%
NUVA
68
+1.3
+1.95%
ONCS
0.92
-0.06
-5.93%
ONVO
2.14
-0.04
-1.83%
OREX
2.43
0.00
0.00%
OTIC
19.45
+2.25
+13.08%
QDEL
32.93
-0.22
-0.66%
RCPT
231.96
0.00
0.00%
RGLS
0.882
-0.057
-6.0390%
RMD
72.44
-0.83
-1.13%
SCIE
0
+0.00
+50.0000%
SPHS
1.85
+0.02
+1.09%
SRNE
1.65
-0.12
-7.04%
TROV
0.8
-0.05
-5.66%
VICL
2.41
-0.06
-2.43%
VOLC
18
0.00
0.00%
ZGNX
11.45
+0.2
+1.78%
ACAD
32.11
+0.22
+0.69%
AEMD
1.59
-0.09
-5.36%
APRI
1.35
0.00
0.00%
ARNA
21.27
-0.12
-0.56%
ATEC
1.68
-0.01
-0.59%
CNAT
5.06
-0.1
-1.94%
CRXM
0.159
+0.001
+0.72152%
CYTX
0.35
-0.02
-4.40%
DXCM
71.22
-0.4
-0.56%
GNMK
9.99
-0.1
-0.99%
HALO
11.9
-0.15
-1.24%
ILMN
193.92
-0.88
-0.45%
INNV
0.109
+0.008
+7.921%
INO
5.64
0.00
0.00%
ISCO
1.3
-0.05
-3.70%
ISIS
57.56
0.00
0.00%
LGND
127.02
+0.1
+0.08%
LPTN
2.93
-2.93
-100.00%
MBVX
0.511
-0.04
-7.1818%
MEIP
2.77
-0.02
-0.72%
MNOV
4.69
+0.09
+1.96%
MRTX
4.9
+0.05
+1.03%
MSTX
0.13
-0.01
-5.28%
NBIX
54.04
+0.06
+0.11%
NUVA
68
+1.3
+1.95%
ONCS
0.92
-0.06
-5.93%
ONVO
2.14
-0.04
-1.83%
OREX
2.43
0.00
0.00%
OTIC
19.45
+2.25
+13.08%
QDEL
32.93
-0.22
-0.66%
RCPT
231.96
0.00
0.00%
RGLS
0.882
-0.057
-6.0390%
RMD
72.44
-0.83
-1.13%
SCIE
0
+0.00
+50.0000%
SPHS
1.85
+0.02
+1.09%
SRNE
1.65
-0.12
-7.04%
TROV
0.8
-0.05
-5.66%
VICL
2.41
-0.06
-2.43%
VOLC
18
0.00
0.00%
ZGNX
11.45
+0.2
+1.78%
Home » Archive by Category

Syndication

Environmental Inspector/Biological Monitor (San Diego County, CA)

August 11, 2017 – 7:49 am

About Insignia Environmental
Insignia Environmental (Insignia) is a growing environmental consulting company focused on the needs of energy and infrastructure clients. Our staff has a foundation in engineering, science, and real-world construction e …

GSK Hands Nerve Drug Back to Ionis as RNA Battle Heats Up

August 11, 2017 – 4:33 am

A race is on to bring two new RNA-based drugs for a rare, debilitating nerve disease called familial amyloid polyneuropathy (FAP). And GlaxoSmithKline has just dropped out of it. This morning, Ionis…

[[Click headline to continue reading.]]

Bio Roundup: $1B Deals, Data Bumps, Acorda’s Lumps, Generic OKs & More

August 11, 2017 – 2:55 am

With President Trump holed up in New Jersey, rattling his saber at Kim Jong-un and Mitch McConnell and ignoring his own commission’s advice on the opioid crisis, there was still life sciences…

[[Click headline to continue reading.]]

Part Time Inventory Coordinator – VWR – San Diego, CA

August 10, 2017 – 8:20 pm

With sales in excess of $4.3 billion in 2015, VWR enables science for customers in the pharmaceutical, biotechnology, industrial, education, government and…From VWR – Fri, 11 Aug 2017 04:20:16 GMT – View all San Diego, CA jobs

Research Scientist in Protein Chemistry (San Diego)

August 10, 2017 – 2:43 pm

Accelagen is seeking a highly motivated candidate to fill a Research Scientist position. Extensive experience in protein expression and purification is required.
Responsibilities:
 Perform tasks in all aspects of recombinant protein express …

Marketing Manager

August 10, 2017 – 2:40 pm

Marketing Manager
BroadPharm is a leading customer-focused biotech company in San Diego, we are looking for a highly motivated and experienced marketing manager for strengthening our Sales & Marketing department. This is a full-time position wit …

Full-Time Hourly Lab Technician – Closing Shift (Sorrento Valley)

August 10, 2017 – 2:37 pm

An immediate position is available at a Sorrento Valley biotech company for a Full Time Hourly Laboratory Technician.
Responsibilities/Job description:
-Perform basic lab duties such as measuring concentrations and preparing dilutions on samples, a …

Regulatory Project Manager

August 10, 2017 – 2:34 pm

Regulatory Affairs Project Manager — San Diego, CA Manages the regulatory aspects of multiple programs, including planning and executing regulatory strategies to facilitate regulatory approvals and maintain compliance. This is a Regulatory site-lead PM po

Sophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights

August 10, 2017 – 1:15 pm

SAN DIEGO and VANCOUVER, British Columbia, Aug. 10, 2017 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a late stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases, today reported financial results for the three and six months ended June 30, 2017 and key corporate highlights.

Key Corporate Highlights:

  • Phase 2b Localized Prostate Cancer Study Underway. On June 8, 2017, the Company announced that the first patient had been dosed in its Phase 2b study to evaluate the safety and tolerability of a single dose of topsalysin in focally treating men with clinically significant localized prostate cancer. Topsalysin (PRX302) is an innovative, first-in-class pore-forming protein engineered to be activated only in the presence of enzymatically-active PSA, which is only found within the prostate. This study is enrolling approximately 40 patients at clinical sites in the UK and US. The Company expects to receive the 24- week biopsy data for all patients from the first dose of topsalysin in the first quarter of 2018 assuming enrollment is completed as expected.

    The Phase 2b study includes an option to re-treat patients with a second dose of topsalysin, with a targeted biopsy to occur 24 weeks following the second dose. The Company expects to have complete data on all patients who receive a second dose by the fourth quarter of 2018 assuming enrollment is completed as expected.

  • Added to Russell Microcap Index®. In June 2017, the Company was added to the Russell Microcap® Index. Russell indices are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.
  • Filing of New Form S-3. In anticipation of the expiration of the company’s existing Form S-3 shelf registration statement filed in September 2014, Sophiris will file a new Form S-3 today with the Securities and Exchange Commission to register securities which could be issued in the future.

“Topsalysin is a highly potent ablative agent, which we administer by an ultrasound-guided injection directly into a tumor, previously confirmed by biopsy. We are using state of the art commercially available software in order to increase the precision by which the physician administers topsalysin into the pre-identified tumor,” said Randall E. Woods, president and CEO of Sophiris. “We are working toward completion of enrollment, and we would like to thank the investigators, study coordinators and patients for their participation in this exciting study.”

Financial Results:

At June 30, 2017, the Company had cash, cash equivalents and securities available-for-sale of $24.0 million and working capital of $23.4 million. The Company expects that its cash and cash equivalents will be sufficient to fund its operations through the end of 2018. The Company is currently not planning on pursuing a second Phase 3 trial in BPH, unless the Company can secure a development partner to fund a new clinical trial or the Company obtains other financing.  

For the three months ended June 30, 2017

The Company reported net income of $0.6 million or $0.02 per share for the three months ended June 30, 2017 compared to a net loss of $4.1 million or ($0.21 per share) for the three months ended June 30, 2016. The net income for the three months ended June 30, 2017 was driven by a non-cash gain related to the revaluation of the Company’s warrant liability. See an additional discussion below related to this item.

Research and development expenses

Research and development expenses were $1.4 million for the three months ended June 30, 2017, compared to $1.0 million for the three months ended June 30, 2016. The increase in research and development costs are primarily attributable to increases in the costs associated with the Company’s Phase 2b clinical trial for the focal treatment of localized prostate cancer, costs associated with manufacturing activities for topsalysin and non-cash stock-based compensation expense. These increases are partially offset by decreases in costs associated with our completed Phase 2a proof of concept clinical trial for low to intermediate risk prostate cancer and personnel related costs.

General and administrative expenses

General and administrative expenses were $1.4 million for the three months ended June 30, 2017 and 2016. General and administrative expense included non-cash stock-based compensation expense of $0.3 million for the three months ended June 30, 2017 as compared to $0.1 million for the three months ended June 30, 2016. This increase was offset by decreases for personnel related costs.

Gain (loss) on revaluation of the warrant liability

Gain on revaluation of the warrant liability was $3.3 million for the three months ended June 30, 2017 compared to a loss of $1.6 million for the three months ended June 30, 2016. Because these warrants may require us to pay the warrant holder cash under certain provisions of the warrant, we account for these warrants as a liability and we are required to calculate the fair value of these warrants each reporting date. This non-cash gain is associated with a reduction in the fair value of the Company’s warrant liability which is calculated using a Black-Scholes pricing model. Certain inputs utilized in the Company’s Black-Scholes fair value calculation may fluctuate in future periods based upon factors which are outside of the Company’s control. A significant change in one or more of these inputs used in the calculation of the fair value may cause a significant change to the fair value of the Company’s warrant liability, which could also result in material non-cash gain or loss being reported in the Company’s consolidated statement of operations and comprehensive loss.

For the six months ended June 30, 2017

The Company reported a net loss of $2.0 million or ($0.07 per share) for the six months ended June 30, 2017 compared to a net loss of $6.3 million or ($0.35 per share) for the six months ended June 30, 2016.

Research and development expenses

Research and development expenses were $2.6 million for the six months ended June 30, 2017 compared to $1.9 million for the six months ended June 30, 2016. The increase in research and development costs are primarily attributable to increases in the costs associated with the Company’s Phase 2b for the focal treatment of localized prostate cancer, costs associated with the manufacturing activities for topsalysin and the non-cash stock-based compensation expense. These increases are partially offset by decreases in costs associated with our completed Phase 2a proof of concept clinical trial for low to intermediate risk prostate cancer and personnel related costs.

General and administrative expenses

General and administrative expenses were $2.7 million for the six months ended June 30, 2017 compared to $2.5 million for the six months ended June 30, 2016. The increase is primarily due to an increase in professional services and non-cash stock-based compensation expense. These increases are partially offset by the decreases in personnel related costs, legal and closing costs which were expensed as they were allocated to the warrants issued in our completed financing during the six months ended June 30, 2016.

Gain (loss) on revaluation of the warrant liability

Gain on revaluation of the warrant liability was $3.2 million for the six months ended June 30, 2017 as compared to a loss of $1.6 million for the six months ended June 30, 2016. This non-cash gain is associated with a reduction in the fair value of our warrant liability.

About Sophiris

Sophiris Bio Inc. is a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells. More than 400 patients have received topsalysin, which continues to appear to be safe and well tolerated. For more information, please visit www.sophirisbio.com.

Certain statements included in this press release may be considered forward-looking, including the quote of Sophiris’ President and CEO, expectations about further development of topsalysin (PRX302), including the timing of expected results, statements about warrant liability and statements related to Sophiris’ liquidity or capital requirements. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Some of the risks and uncertainties that could cause actual results, performance or achievements to differ include without limitation, risks associated with clinical development, including the risk that the enrollment of the Phase 2b study will not be completed when expected and that results will not be available when expected and risks that the results of the Phase 2b study will not replicate the results of the completed Phase 2 study of topsalysin for the treatment of localized low to intermediate risk prostate cancer or the study endpoint[s] will not be achieved, and other risks and uncertainties identified by Sophiris in its public securities filings with the SEC. All forward-looking statements are based on Sophiris’ current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, clinical trial results, market acceptance, ability to raise capital and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
Peter Slover
Chief Financial Officer
(858) 777-1760

Corporate Communications Contact:
Jason Spark                                          
Canale Communications             
(619) 849-6005
jason@canalecomm.com   

Sophiris Bio Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share amounts)

(Unaudited)

June 30

December 31,

2017

2016

Assets:

Current assets:

Cash and cash equivalents

$

6,824

$

12,800

Securities available-for-sale

17,205

16,201

Other receivables

69

128

Prepaid expenses

948

846

Total current assets

25,046

29,975

Property and equipment, net

2

4

Other long-term assets

19

Total assets

$

25,048

$

29,998

Liabilities and shareholders’ equity:

Current liabilities:

Accounts payable

$

506

$

459

Accrued expenses

1,154

1,762

Total current liabilities

1,660

2,221

Warrant liability

10,162

13,396

Stock-based compensation liability

57

Total liabilities

11,822

15,674

Shareholders’ equity:

Common shares, unlimited authorized shares, no par value; 30,111,153 and 30,107,644 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively

131,246

131,245

Contributed surplus

24,824

23,900

Accumulated other comprehensive gain

85

99

Accumulated deficit

(142,929)

(140,920)

Total shareholders’ equity

13,226

14,324

Total liabilities and shareholders’ equity

$

25,048

$

29,998

 

Sophiris Bio Inc.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended June  30,

Six Months Ended June 30,

2017

2016

2017

2016

Operating expenses:

Research and development

$

1,387

$

978

$

2,595

$

1,907

General and administrative

1,367

1,357

2,736

2,521

Total operating expenses

2,754

2,335

5,331

4,428

Other income (expense):

Interest expense

(137)

(287)

Interest income

53

3

103

7

Gain (Loss) on revaluation of warrant liability

3,320

(1,619)

3,234

(1,619)

Other expense, net

(9)

(3)

(16)

(7)

Total other income (expense)

3,364

(1,756)

3,321

(1,906)

Net income (loss)

$

610

$

(4,091)

$

(2,010)

$

(6,334)

Basic income (loss) per share

$

0.02

$

(0.21)

$

(0.07)

$

(0.35)

Diluted income (loss) per share

$

0.02

$

(0.21)

$

(0.07)

$

(0.35)

Weighted average number of outstanding shares – basic

30,111

19,340

30,111

18,292

Weighted average number of outstanding shares –diluted

30,515

19,340

30,111

18,292

 

View original content with multimedia:http://www.prnewswire.com/news-releases/sophiris-bio-reports-second-quarter-financial-results-and-key-corporate-highlights-300503061.html

SOURCE Sophiris Bio Inc.

Aethlon Medical Announces Fiscal 2018 First Quarter Results

August 10, 2017 – 12:15 pm

SAN DIEGO, Aug. 10, 2017 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal first quarter ended June 30, 2017.

The Company disclosed that it has finalized an Expedited Access Pathway (EAP) program submission that its regulatory advisors will now provide to the United States Food and Drug Administration (FDA).  The submission requests that the Aethlon Hemopurifier® be included in the EAP program. 

The FDA established the EAP program for medical devices that demonstrate the potential to address unmet medical needs for life threatening or irreversibly debilitating diseases or conditions that are subject to premarket approval applications (PMA), premarket notification (510[k]) or requests for De Novo designation.  A criterion for EAP program eligibility includes medical devices that represent breakthrough technologies with the potential to address life threatening disease conditions for which no approved or cleared treatment alternatives exist.

The Hemopurifier has been designed for the single-use removal of viral pathogens from the circulatory system of infected individuals.  The device is a candidate broad-spectrum treatment countermeasure against life-threatening viruses that are not addressed with approved antiviral drug therapies.

Previous treatment experience against a life-threatening virus not addressed with an approved antiviral drug includes the successful treatment of Ebola virus, for which Aethlon subsequently received FDA clearance of emergency-use and compassionate-use treatment protocols.   Aethlon has also concluded an FDA-approved feasibility study to support the advancement of the Hemopurifier as a treatment countermeasure against life-threatening viruses that are not addressed with a market cleared therapy.

The Hemopurifier has also been validated in vitro to effectively capture a broad-spectrum of life-threatening viral pathogens, many of which are not treatable with approved antiviral drug agents.  The capture validation of mosquito-borne viruses that are not addressed with an approved antiviral drug includes Chikunguya virus, Dengue virus, West Nile virus and Zika virus.

Beyond Ebola treatment experience, the capture validation of bioterror and pandemic threat viruses that are not addressed with an approved antiviral drug includes Lassa virus, MERS-CoV and Monkeypox virus, which is a surrogate for human Smallpox infection.  Studies of Marburg virus are currently being conducted.

The capture validation of pandemic influenza viruses includes virulent H5N1 Bird-Flu virus, H1N1 Swine Flu virus and the reconstructed Spanish Flu virus of 1918.

The Hemopurifier has additionally been validated to capture latent viral pathogens that can contribute to increased mortality rates in immune-compromised individuals. Such validations include Cytomegalovirus, Epstein-Barr virus and Herpes-simplex virus-1.  Based on previous preclinical and human clinical studies, Aethlon believes the Hemopurifier may also have utility in addressing drug-resistant viral strains that can emerge in HIV and Hepatitis-C infected individuals.

Aethlon is also advancing the Hemopurifier to fulfill the broad-spectrum treatment objectives of the 2016 Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) initiative.  The PHEMCE initiative defines the strategic plan of the U.S. government to protect its citizens against bioterror and pandemic threats.  Based on preclinical and clinical studies, the Company believes the Hemopurifier to be most advanced broad-spectrum treatment candidate. Included among Aethlon’s goals is the procurement of the Hemopurifier into the U.S. government’s strategic national stockpile. 

Financial Results

The net loss for the June 2017 quarter was $1.8 million, or $0.21 per share, compared to a net loss for the June 2016 quarter of $2.1 million, or $0.28 per share.

Consolidated operating expenses were $1.16 million in the June 2017 quarter compared to $1.14 million in the June 2016 quarter, an increase of approximately $20,000. This increase was primarily due to an increase in payroll and related expenses of approximately $290,000. However, the increase in payroll and related expenses was driven by a $230,000 increase in our non-cash, stock-based compensation due to the vesting of restricted stock units granted during the fiscal year.

Excluding that non-cash increase, our overall cash operating expenses actually decreased by approximately $210,000 from reductions in our professional fees and general and administrative expenses.  Specifically, our professional fees decreased by approximately $225,000 and our general and administrative expenses declined by approximately $37,000.

The Company had other expense of approximately $685,000 in the June 2017 quarter compared to approximately $1 million in the June 2016 quarter, a decrease of approximately $315,000

At June 30, 2017, the Company had a cash balance of approximately $327,000. The Company has an active At The Market financing facility to raise additional capital as needed.

The unaudited condensed consolidated balance sheet for June 30, 2017 and the unaudited condensed consolidated statements of operations for the quarters ended June 30, 2017 and 2016 follow at the end of this release.

Conference Call

Aethlon will hold a conference call for investors on Thursday, August 10, 2017 at 1:30 p.m. PT (4:30 p.m. ET). To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and international callers should call 1-412-317-5442. All callers should ask for the Aethlon Medical Inc., conference call. The conference call will also be available through a live webcast at www.aethlonmedical.com. Details for the webcast may be found on the Company’s IR events page at http://ir.aethlonmedical.com.

A replay of the call will be available approximately one hour after the end of the call through August 17, 2017. The replay can be accessed via Aethlon Medical’s website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay conference ID number is 10111295.

About Aethlon Medical, Inc.

Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer.  To augment the body’s natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals.  The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism.  The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens.  At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study.  Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.  Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer’s disease (AD) and Chronic Traumatic Encephalopathy (CTE).  ESI’s TauSome™ biomarker is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals.  Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.  You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “will,” “projections,” “estimate,” or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company’s ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company’s clinical programs or provide market clearance of the Company’s products, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company’s proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2017, and in the Company’s other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com

Investor Relations:
John Marco
CORE IR
516 222 2560
johnm@coreir.com

 

AETHLON MEDICAL, INC.

Condensed Consolidated Balance Sheet

ASSETS

June 30, 2017

March 31, 2017

(unaudited)

(unaudited)

CURRENT ASSETS

Cash

$327,206

$1,559,701

Prepaid expenses

38,450

37,551

TOTAL CURRENT ASSETS

365,656

1,597,252

Property and equipment, net

45,893

29,223

Patents, net

82,705

84,996

Other assets

14,897

14,897

TOTAL NONCURRENT ASSETS

143,495

129,116

TOTAL ASSETS

$509,151

$1,726,368

LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY

CURRENT LIABILITIES

Accounts payable 

277,094

484,423

Due to related parties

48,366

57,866

Other current liabilities

82,845

69,467

TOTAL CURRENT LIABILITIES

408,305

611,756

NONCURRENT LIABILITIES

Convertible notes payable, non-current portion, net

1,050,911

519,200

TOTAL NONCURRENT LIABILITIES

1,050,911

519,200

TOTAL LIABILITIES

1,459,216

1,130,956

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ (DEFICIT) EQUITY

Common stock, par value of $0.001, 30,000,000 shares authorized; 8,869,571 and 8,797,086 shares issued and outstanding as of June 30, 2017 and March 31, 2017, respectively

8,869

8,796

Additional paid-in capital

94,745,740

94,445,739

Accumulated deficit

(95,619,939)

(93,778,156)

TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY BEFORE NONCONTROLLING INTERESTS

(865,330)

676,379

Noncontrolling interests

(84,735)

(80,967)

TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY

(950,065)

595,412

TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY

$509,151

$1,726,368

 

AETHLON MEDICAL, INC.

Condensed Consolidated Statements of Operations

For the three month periods ended June 30, 2017 and 2016

Three Months

Three Months

Ended 6/30/17

Ended 6/30/16

(unaudited)

(unaudited)

Government contract income

$                     –

$              4,635

  Total revenues

4,635

OPERATING EXPENSES

Professional fees

343,023

567,749

Payroll and related

630,227

344,987

General and administrative

186,999

223,551

  Total operating expenses

1,160,249

1,136,287

OPERATING LOSS

(1,160,249)

(1,131,652)

OTHER (INCOME) EXPENSE

Loss on share for warrant exchanges

119,789

Loss on debt extinguishment

376,909

616,889

Warrant repricing expense

345,841

Interest and other debt expenses

188,604

42,167

685,302

1,004,897

NET LOSS BEFORE NONCONTROLLING INTERESTS

$(1,845,551)

$(2,136,549)

Loss attributable to noncontrolling interests

(3,769)

(7,732)

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

$(1,841,782)

$(2,128,817)

Basic and diluted net loss available to common stockholders per share

$          (0.21)

$          (0.28)

Weighted average number of common shares outstanding

8,805,522

7,622,393

 

 

View original content:http://www.prnewswire.com/news-releases/aethlon-medical-announces-fiscal-2018-first-quarter-results-300502952.html

SOURCE Aethlon Medical, Inc.